OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Thoracic Oncology is 59. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Meeting Announcements	661
Better Together: Advancing Tobacco Use Treatment and Lung Cancer Screening	346
In This Issue/Research Watch/News in Brief	318
Board of Directors	303
FP14.05 LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).	268
Do We Really Understand the Relationship Between Expression of ACE2 and Coronavirus Disease 2019 Lung Pathophysiology?	209
Reply to Kus and Aktas	198
New Pulmonary Infiltrates Observed on Computed Tomography-Based Image Guidance for Radiotherapy Warrant Diagnostic Workup for Coronavirus Disease 2019	194
P76.95 Brief Report: Immunochemotherapy in Five Patients with EGFR Exon 20 Insertion Advanced Lung Adenocarcinoma	189
Erratum	185
Editorial Commentary: Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC	185
Board of Directors	158
“Tumor-free survival” Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC	157
A Response to the Letter to the Editor: “Prognostic Factors for Survival After Thymoma Distant Recurrence Resection”	152
Table of Contents	146
Editorial Comment: Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer	145
Tobacco News Update—From the IASLC Tobacco Control Committee	144
Letter Regarding “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib”	142
P65.04 Tracking circRNAs in Lung Adenocarcinoma Samples as Promising Biomarkers for Cancer Detection using the NanoString nCounter®	141
Response to Commentary on “EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47”	138
Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study	136
Board of Directors	116
Socioeconomic Inequalities in Novel NSCLC Treatments During the Era of Tumor Biomarker-Guided Therapy: A Population-Based Cohort Study in a Publicly Funded Health Care System	112
The HILUS-Trial—a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy	111
In This Issue	108

Meeting Announcements	104
A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC	95
Table of Contents	94
Board of Directors	91
Future Radiation Oncology: The Role of Personalization and Standardization in Stereotactic Body Radiotherapy	91
Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma	91
The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the “T” Descriptors in the Forthcoming Ninth Edition of the TNM Classification for P	90
Treatment of Leptomeningeal Metastases: New Hammer, the Same Nail	90
In This Issue	89
Table of Contents	89
Editorial Board	88
PP01.67 Evaluating immune-related adverse events (irAEs) in a real-world cohort with lung cancer receiving immunotherapy	87
PP01.112 Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real-World Study	86
PP01.109 Concordance of Breast Density Between Low-Dose CT and Mammogram	82
PP01.18 Real-world evaluation of racial and socioeconomic disparities in patients with NSCLC treated with immunotherapy	81
OA01.01 Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors	78
PPD01.02 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 Trial	75
PP01.85 A Phase 2/3 Study of Fianlimab, Cemiplimab, plus Chemotherapy Versus Cemiplimab plus Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer	75
PP01.172 It's Never Too Late To Quit	75
PP01.117 Real-World Effectiveness and Safety Profile of Lurbinectedin and Other Second-Line Treatments in Small Cell Lung Cancer	73
PP01.101 Estimated Cost of Adverse Events and Surgery for Resectable Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Nivolumab Plus Platinum-Doublet Chemotherapy	73
PP01.40 Treatment Patterns and Survival Outcomes of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Survival at a Safety-Net Hospital	73
PP01.65 Efficacy and Safety of Dose-Escalated Alectinib in Patients with Metastatic ALK-positive NSCLC and CNS Relapse on Standard Dose Alectinib	72
PPD01.06 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-2 Study	70
PP01.06 Role of number of pathologic N2 stations for future AJCC lung cancer staging versions	67
PP01.23 Plasma cell-free RNA PD-L1 or Tissue PD-L1 Protein Expression and Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer	67
PP01.136 Understanding Experiences of Cancer-Related Fatigue in Patients with Lung Cancer After Their Cancer Treatment: A Qualitative Content Analysis	66
PP01.119 Real-World Use of Lurbinectedin in Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis	66
PP01.169 Promotion of Low-Dose Computed Tomography Screening and Blood Biomarkers in Minority Communities for Early Detection of Lung Cancer in Northern Illinois	65
PP01.26 Proprietary vs Open-Source Radiomic Platform for Lung Cancer Diagnosis	63
PP01.74 LiquidHALLMARK detects more tissue-confirmed guideline-recommended biomarkers than Guardant360 for lung cancer: a prospective multicenter study	63
PP01.90 Real-world Demographics, Clinical Characteristics, Treatment Patterns and Clinical Outcomes for US Patients with Limited-Stage SCLC (LS-SCLC)	62
PP01.20 Hospitalization patterns for immune-related adverse events in patients with NSCLC treated with immunotherapy vs chemo-immunotherapy	61
PP01.108 Trial in Progress: Shared Decision-Making Encounter Tool for Adjuvant Treatment of Lung Cancer: Randomized Control Trial	59